LLY

977.17

+3.12%↑

JNJ

220.76

-0.16%↓

ABBV

202.8

+0.83%↑

UNH

379.75

+0.08%↑

AZN

183.54

+0.67%↑

LLY

977.17

+3.12%↑

JNJ

220.76

-0.16%↓

ABBV

202.8

+0.83%↑

UNH

379.75

+0.08%↑

AZN

183.54

+0.67%↑

LLY

977.17

+3.12%↑

JNJ

220.76

-0.16%↓

ABBV

202.8

+0.83%↑

UNH

379.75

+0.08%↑

AZN

183.54

+0.67%↑

LLY

977.17

+3.12%↑

JNJ

220.76

-0.16%↓

ABBV

202.8

+0.83%↑

UNH

379.75

+0.08%↑

AZN

183.54

+0.67%↑

LLY

977.17

+3.12%↑

JNJ

220.76

-0.16%↓

ABBV

202.8

+0.83%↑

UNH

379.75

+0.08%↑

AZN

183.54

+0.67%↑

Home・Stock List・Denali Therapeutics Inc

Denali Therapeutics Inc

Open

SectorHealthcare

19.54 0.21

Buy Sell

Overview

Share price change

24h

Current

Min

19.5

Max

20.52

Key metrics
By Trading Economics
Income	-1.6M -129M
Employees	503
EBITDA	8.9M -125M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+81.65% upside

Dividends
By Dow Jones
Next Earnings	11 May 2026

Market Stats
By TradingEconomics
Market Cap	-295M 3B
Previous open	19.33
Previous close	19.54

News Sentiment

By Acuity

50%

153 / 347 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

13.355 / 16.44 Support & Resistance

Denali Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

10 May 2026, 23:47 UTC

Market Talk

Gold Falls on Renewed Inflation Concerns -- Market Talk

10 May 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10 May 2026, 23:38 UTC

Market Talk

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10 May 2026, 23:14 UTC

Market Talk

Australia's Political Map Continues to Be Redrawn -- Market Talk

10 May 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Elevra Lithium: Expects Deal to Close in 1Q FY27

10 May 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10 May 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10 May 2026, 10:21 UTC

Earnings

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9 May 2026, 06:05 UTC

Earnings

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 May 2026, 23:55 UTC

Earnings

Review & Preview: Still Going Strong -- Barrons.com

8 May 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 May 2026, 20:49 UTC

Earnings

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 May 2026, 20:25 UTC

Earnings

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 May 2026, 19:43 UTC

Earnings

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 May 2026, 19:43 UTC

Earnings

Cencosud 1Q Net $115M

8 May 2026, 19:20 UTC

Market Talk

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 May 2026, 19:18 UTC

Earnings

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 May 2026, 19:16 UTC

Earnings

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 May 2026, 19:08 UTC

Earnings

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 May 2026, 19:05 UTC

Earnings

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 May 2026, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 May 2026, 18:51 UTC

Earnings

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 May 2026, 18:49 UTC

Earnings

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 May 2026, 18:41 UTC

Earnings

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 May 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 May 2026, 17:14 UTC

Earnings

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 May 2026, 17:04 UTC

Market Talk

Zcash Caps Off Parabolic Week -- Market Talk

8 May 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 May 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 May 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Peer Comparison

Price change

Denali Therapeutics Inc Forecast

Price Target

By TipRanks

81.65% upside

12 Months Forecast

Average 35.64 USD 81.65%

High 42 USD

Low 23 USD

Based on 14 Wall Street analysts offering 12 month price targets forDenali Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Based on 14 analysts giving stock ratings to Denali Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

13.355 / 16.44Support & Resistance

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

153 / 347 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.